Robert Alan Figlin

Title: Innovations by Robert Alan Figlin

Introduction

Robert Alan Figlin is a notable inventor based in Los Angeles, CA. He has made significant contributions to the field of immunotherapy, particularly in enhancing anti-tumor responses in human patients. His work focuses on the development of methods that utilize specific cytokines to improve the immune response against tumors.

Latest Patents

Robert Alan Figlin holds a patent titled "Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient." This patent describes innovative methods for enhancing the development of antigen-presenting cells (APCs) from precursor cells. The invention involves administering a combination of GM-CSF and IL-4, which can be used as a form of cytokine immunotherapy. The patent outlines various embodiments, including systemic administration of these cytokines to enable APCs to access tumor antigens directly within the patient. Additionally, it discusses co-administration of tumor-associated or tumor-specific antigens to induce antigen-specific immunity mediated by APCs. The ultimate goal of this invention is to achieve reduced tumor burden in patients.

Career Highlights

Robert Alan Figlin is affiliated with the University of California, where he continues to advance research in immunotherapy. His work has garnered attention for its potential to improve cancer treatment outcomes through innovative approaches to immune system modulation.

Collaborations

Some of his notable coworkers include Michael Derek Roth and Sylvia Marie Kiertscher. Their collaborative efforts contribute to the ongoing research and development in the field of cancer immunotherapy.

Conclusion

Robert Alan Figlin's contributions to the field of immunotherapy through his innovative patent demonstrate his commitment to enhancing cancer treatment. His work has the potential to significantly impact patient outcomes and advance the understanding of immune responses to tumors.